Skip to main content

Table 4 Multivariate Analyses of Survival in the Second Study Population (N = 322)

From: Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

Variable

DDFS

DSS

HR

95% CI

P

HR

95% CI

P

Age

      

 > 50 yr. vs. ≤50 yr

0.56

0.29–1.07

0.08

0.34

0.13–0.92

0.033

ER status

      

 Negative vs. Positive

1.01

0.49–2.06

0.99

0.58

0.19–1.75

0.33

PR status

      

 Negative vs. Positive

0.82

0.39–1.72

0.60

0.86

0.30–2.50

0.79

HER2 status

      

 Positive vs. Negative

1.72

0.80–3.73

0.17

4.23

1.60–11.46

0.004

Tumor size

      

 > 2 cm vs. ≤2 cm

0.76

0.40–1.42

0.39

1.01

0.41–2.50

0.98

Lymph node status

      

 Positive vs. Negative

2.68

1.43–5.03

0.002

3.68

1.39–9.75

0.009

Adjuvant chemotherapy

      

 C vs. no therapy

1.71

0.38–7.79

0.49

1.46

0.29–7.29

0.64

 E vs. no therapy

2.53

0.44–14.62

0.30

1.67

0.20–13.69

0.63

 C + E vs.no therapy

2.11

0.47–9.47

0.33

0.92

0.17–5.01

0.63

RECQL protein expression

      

 Low vs. High

2.12

1.16–3.88

0.015

2.09

0.85–5.13

0.06

  1. Abbreviations: RFS, recurrence-free survival; DRFS, distant recurrence-free survival; DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2;C,chemotherapy; E, endocrinotherapy; C + E, chemotherapy and endocrinotherapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us